Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer

• F. Ayala de la Peña ^[1] ; B. Ortiz-Muñoz ^[2] ; T. Quintanar-Verdúguez ^[3] ; J. D. Santotoribio ^[4] ; S. de la Cruz ^[5] ; J. Trapé-Pujol ^[8] ; E. Galve-Calvo ^[6] ; J. M. Augé-Fradera ^[9] ; J. García-Gómez ^[10] ; Á. González-Hernández ^[7]
  1. [1] Hospital Morales Meseguer

     Hospital Morales Meseguer

     Murcia, España

     
  2. [2] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  3. [3] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  4. [4] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  5. [5] Gobierno de Navarra

     Gobierno de Navarra

     Pamplona, España

     
  6. [6] Hospital Universitario de Basurto

     Hospital Universitario de Basurto

     Bilbao, España

     
  7. [7] Clínica Universitaria de Navarra

     Clínica Universitaria de Navarra

     Pamplona, España

     
  8. [8] Althaia Xarxa Assistencial Universitaria
  9. [9] Hospital Clinic, Barcelona
  10. [10] Complexo Hospitalario de Ourense

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 7 (July), 2021, págs. 1272-1280
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The measurement of circulating tumour markers (TMs) for the diagnosis or monitoring of breast cancer has sometimes been considered of limited utility. In addition to the overinterpretation of irrelevant changes in marker levels, the characteristics of the patient, the disease or other pathologies that can modify them are often not considered in their evaluation. On the other hand, there are recent data on the relationship of TMs with molecular subtypes and on their prognostic value, the knowledge of which may improve their clinical utility. This consensus article arises from a collaboration between the Spanish Society of Laboratory Medicine (SEQCML) and the Spanish Society of Medical Oncology (SEOM). It aims to improve the use and interpretation of circulating TMs in breast cancer. The text summarizes the current knowledge and available evidence on the subject and proposes a series of recommendations mainly focussed on the indication, the frequency of testing and the factors that should be considered for correctly interpreting changes in the levels of TMs.